{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:58:08Z","timestamp":1777579088459,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004897","name":"European Organisation for Research and Treatment of Cancer","doi-asserted-by":"publisher","award":["008\\u20132023"],"award-info":[{"award-number":["008\\u20132023"]}],"id":[{"id":"10.13039\/501100004897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.critrevonc.2025.105100","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T16:20:58Z","timestamp":1766506858000},"page":"105100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["What\u2019s missing in patient-reported outcome reporting? A scoping review and aggregated trial-level analysis of completion rates in oncology randomized controlled trials"],"prefix":"10.1016","volume":"218","author":[{"given":"Daniela","family":"Krepper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niclas J.","family":"Hubel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel M.","family":"Vorbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lotte","family":"van der Weijst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigirl","family":"Machingura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Seidl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes M.","family":"Giesinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Sztankay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scottie","family":"Kern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Fitzsimmons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeline","family":"Pe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Holzner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4670-7517","authenticated-orcid":false,"given":"Jens","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.105100_bib1","unstructured":"FDA. Guidance for Industry. 2009;43."},{"key":"10.1016\/j.critrevonc.2025.105100_bib2","unstructured":"European Medicines Agency. Guideline on Missing Data in Confirmatory Clinical Trials [Internet]. 2010 [cited 2023 Mar 17]. Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-missing-data-confirmatory-clinical-trials_en.pdf\u3009."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.105100_bib3","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1056\/NEJMsr1203730","article-title":"The prevention and treatment of missing data in clinical trials","volume":"367","author":"Little","year":"2012","journal-title":"N. Engl. J. Med"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105100_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010938","article-title":"Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review","volume":"6","author":"Mercieca-Bebber","year":"2016","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105100_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/nop\/npab043","article-title":"Missing repeated measures data in clinical trials","volume":"9","author":"Pugh","year":"2022","journal-title":"Neuro-Oncol. Pr."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105100_bib6","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S1470-2045(19)30790-9","article-title":"International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium","volume":"21","author":"Coens","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.105100_bib7","unstructured":"European Society for Medical OncologyESMO). ESMO MCBS QoL Checklist [Internet]. 2022 [cited 2025 July 4]. Available from: \u3008https:\/\/dam.esmo.org\/image\/upload\/ESMO-MCBS-QoL-Checklist.pdf\u3009."},{"key":"10.1016\/j.critrevonc.2025.105100_bib8","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1477-7525-11-184","article-title":"The CONSORT Patient-Reported Outcome (PRO) extension: implications for clinical trials and practice","volume":"11","author":"Calvert","year":"2013","journal-title":"Health Qual. Life Outcomes"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105100_bib9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jama.2017.21903","article-title":"Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension","volume":"319","author":"Calvert","year":"2018","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105100_bib10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40271-014-0090-z","article-title":"Capturing Patient-Reported Outcome (PRO) data electronically: the past, present, and promise of ePRO measurement in clinical trials","volume":"8","author":"Coons","year":"2015","journal-title":"Patient PatientCent. Outcomes Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105100_bib11","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1186\/s13063-022-06955-w","article-title":"Considerations when introducing electronic patient-reported outcome data capture in multicentre oncology randomised controlled trials","volume":"23","author":"Philipps","year":"2022","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105100_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkae002","article-title":"Patient-targeted education (ePRO-E) to increase ePRO intent within an Alliance clinical trial (A221805-SI1)","volume":"8","author":"Smith","year":"2024","journal-title":"JNCI Cancer Spectr."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.105100_bib13","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.2015.63.6480","article-title":"Patient-reported outcomes labeling for products approved by the office of hematology and oncology products of the US Food and Drug Administration (2010-2014)","volume":"34","author":"Gnanasakthy","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105100_bib14","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2025.105100_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114313","article-title":"Improving completion rates of patient-reported outcome measures in cancer clinical trials: Scoping review investigating the implications for trial designs","volume":"212","author":"van der Weijst","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105100_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2023.07.012","article-title":"Information about missing patient-reported outcome data in breast cancer trials is frequently not documented: a scoping review","volume":"162","author":"Krepper","year":"2023","journal-title":"J. Clin. Epidemiol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105100_bib17","doi-asserted-by":"crossref","first-page":"950","DOI":"10.11124\/JBIES-21-00483","article-title":"What are scoping reviews? Providing a formal definition of scoping reviews as a type of evidence synthesis","volume":"20","author":"Munn","year":"2022","journal-title":"JBI Evid. Synth."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105100_bib18","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern Med"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105100_bib19","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.jval.2021.06.003","article-title":"Investigating trends in the quality of reporting of patient-reported outcomes in oncology over time: analysis of 631 randomized controlled trials published between 2004 and 2019","volume":"24","author":"Efficace","year":"2021","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105100_bib20","first-page":"585","article-title":"Past and current practice of patient-reported outcome measurement in randomized cancer clinical trials: a systematic review","volume":"24","author":"Giesinger","year":"2021","journal-title":"Value Health J. Int Soc. Pharm. Outcomes Res"},{"key":"10.1016\/j.critrevonc.2025.105100_bib21","unstructured":"DistillerSR [Internet]. DistillerSR Inc; 2025 [cited 2025 Sept 15]. Available from: \u3008https:\/\/www.distillersr.com\u3009."},{"key":"10.1016\/j.critrevonc.2025.105100_bib22","unstructured":"R. Core Team. R: A language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2021. Available from: \u3008https:\/\/www.R-project.org\/\u3009."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105100_bib23","doi-asserted-by":"crossref","DOI":"10.2196\/jmir.3578","article-title":"Tablet, Web-Based, or Paper Questionnaires for Measuring Anxiety in Patients Suspected of Breast Cancer: Patients\u2019 Preferences and Quality of Collected Data","volume":"16","author":"Barentsz","year":"2014","journal-title":"J. Med Internet Res"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105100_bib24","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40271-019-00376-9","article-title":"Preferences for use and design of electronic patient-reported outcomes in patients with chronic obstructive pulmonary disease","volume":"12","author":"Dumais","year":"2019","journal-title":"Patient PatientCent. Outcomes Res"},{"issue":"16","key":"10.1016\/j.critrevonc.2025.105100_bib25","doi-asserted-by":"crossref","first-page":"5475","DOI":"10.1002\/cam4.4111","article-title":"International perspectives on suboptimal patient-reported outcome trial design and reporting in cancer clinical trials: a qualitative study","volume":"10","author":"Retzer","year":"2021","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105100_bib26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12894-019-0518-9","article-title":"Patient-reported outcomes in randomised clinical trials of bladder cancer: an updated systematic review","volume":"19","author":"van Hemelrijck","year":"2019","journal-title":"BMC Urol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105100_bib27","doi-asserted-by":"crossref","DOI":"10.2196\/28915","article-title":"Data quality of longitudinally collected patient-reported outcomes after thoracic surgery: comparison of paper- and web-based assessments","volume":"23","author":"Yu","year":"2021","journal-title":"J. Med Internet Res"},{"issue":"7347","key":"10.1016\/j.critrevonc.2025.105100_bib28","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1136\/bmj.324.7347.1193","article-title":"Patient non-compliance with paper diaries","volume":"324","author":"Stone","year":"2002","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105100_bib29","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/jnci\/djab177","article-title":"Impact of blinding on patient-reported outcome differences between treatment arms in cancer randomized controlled trials","volume":"114","author":"Efficace","year":"2022","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105100_bib30","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/jnci\/djy181","article-title":"Blinding and patient-reported outcome completion rates in US food and drug administration cancer trial submissions, 2007\u20132017","volume":"111","author":"Roydhouse","year":"2019","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105100_bib31","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s11136-021-02945-8","article-title":"Impact of open-label versus blinded study design on patient-reported outcomes data in randomized clinical trials of immunotherapy in advanced or metastatic cancer patients: a systematic review","volume":"31","author":"Anota","year":"2022","journal-title":"Qual. Life Res"},{"key":"10.1016\/j.critrevonc.2025.105100_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.968272","article-title":"A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020","volume":"9","author":"Teixeira","year":"2022","journal-title":"Front Med"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:02:38Z","timestamp":1773932558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825004883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":32,"alternative-id":["S1040842825004883"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105100","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What\u2019s missing in patient-reported outcome reporting? A scoping review and aggregated trial-level analysis of completion rates in oncology randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105100"}}